智飛生物(300122.SZ):上半年淨利升31.18%至15.05億元
格隆匯8月3日丨智飛生物(300122.SZ)披露2020年半年度報告,報告期內,公司實現營業收入69.94億元,同比增長38.80%;歸屬於母公司所有者的淨利潤15.05億元,同增長31.18%;歸屬於母公司所有者扣除非經常性損益的淨利潤15.13億元,同增長28.58%。
2020年上半年,公司進一步加大研發投入,研發投入金額為1.40億元,較上年同期增長37.03%,穩定、持續的投入,有力的促進了新產品研發進展。報告期內,公司繼續專注生物醫藥主業,穩步推進研發生產,各項工作進展順利。
公司共有11種產品於報告期內上市或銷售,產品覆蓋嬰幼兒、成年以及老年羣體,為全年齡段人羣提供疾病預防和治療解決方案。結核類診斷試劑宜卡是今年第二季度獲批的自研新產品,公司正積極推進該產品的市場準入工作,截至該公告日,該產品已順利准入海南、江西2個省份。
此外,截至報告期末,預充裝ACYW135多糖疫苗已中標22個省級單位,預充裝AC結合疫苗已中標27個省級單位,預充裝Hib疫苗已中標23個省級單位,升級優化產品的廣泛准入,為自主產品推廣銷售奠定了基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.